Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.

Jackson JJ, Ketcham JM, Younai A, Abraham B, Biannic B, Beck HP, Bui MHT, Chian D, Cutler G, Diokno R, Hu DX, Jacobson S, Karbarz E, Kassner PD, Marshall L, McKinnell J, Meleza C, Okal A, Pookot D, Reilly MK, Robles O, Shunatona HP, Talay O, Walker JR, Wadsworth A, Wustrow DJ, Zibinsky M.

J Med Chem. 2019 Jul 11;62(13):6190-6213. doi: 10.1021/acs.jmedchem.9b00506. Epub 2019 Jul 1.

PMID:
31259550
2.

miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells.

Noonan EJ, Place RF, Basak S, Pookot D, Li LC.

Oncotarget. 2010 Sep;1(5):349-58.

3.

Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma.

Whitson JM, Noonan EJ, Pookot D, Place RF, Dahiya R.

Int J Cancer. 2009 Jul 15;125(2):446-52. doi: 10.1002/ijc.24370.

4.

miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.

Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R.

Oncogene. 2009 Apr 9;28(14):1714-24. doi: 10.1038/onc.2009.19. Epub 2009 Mar 2.

PMID:
19252524
5.

Toxic and chemopreventive ligands preferentially activate distinct aryl hydrocarbon receptor pathways: implications for cancer prevention.

Okino ST, Pookot D, Basak S, Dahiya R.

Cancer Prev Res (Phila). 2009 Mar;2(3):251-6. doi: 10.1158/1940-6207.CAPR-08-0146. Epub 2009 Feb 17.

6.

Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.

Basak S, Pookot D, Noonan EJ, Dahiya R.

Mol Cancer Ther. 2008 Oct;7(10):3195-202. doi: 10.1158/1535-7163.MCT-08-0617.

7.

Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification.

Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, Hirata H, Li LC, Zhao H, Okino ST, Place RF, Pookot D, Dahiya R.

Cancer Res. 2008 Apr 15;68(8):2736-44. doi: 10.1158/0008-5472.CAN-07-2290.

8.

Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells.

Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya R, Li LC.

Mol Cancer Ther. 2008 Mar;7(3):698-703. doi: 10.1158/1535-7163.MCT-07-2312.

9.

MicroRNA-373 induces expression of genes with complementary promoter sequences.

Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R.

Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1608-13. doi: 10.1073/pnas.0707594105. Epub 2008 Jan 28. Erratum in: Proc Natl Acad Sci U S A. 2018 Mar 19;:.

10.

A dioxin-responsive enhancer 3' of the human CYP1A2 gene.

Okino ST, Quattrochi LC, Pookot D, Iwahashi M, Dahiya R.

Mol Pharmacol. 2007 Dec;72(6):1457-65. Epub 2007 Sep 4.

PMID:
17785579
11.

Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.

Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M, Dahiya R.

Oncogene. 2007 Dec 6;26(55):7647-55. Epub 2007 Jun 11.

PMID:
17563745
12.

Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.

Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, Majid S, Enokida H, Nakagawa M, Dahiya R.

Clin Cancer Res. 2007 May 1;13(9):2541-8.

13.

Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer.

Okino ST, Pookot D, Majid S, Zhao H, Li LC, Place RF, Dahiya R.

Mol Carcinog. 2007 Oct;46(10):839-46.

PMID:
17415778
14.

Small dsRNAs induce transcriptional activation in human cells.

Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42. Epub 2006 Nov 3.

15.

Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer.

Okino ST, Pookot D, Li LC, Zhao H, Urakami S, Shiina H, Igawa M, Dahiya R.

Cancer Res. 2006 Aug 1;66(15):7420-8.

16.

The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men.

Pookot D, Li LC, Tabatabai ZL, Tanaka Y, Greene KL, Dahiya R.

J Urol. 2006 Aug;176(2):793-6. Erratum in: J Urol. 2006 Oct;176(4 Pt 1):1688.

PMID:
16813949
17.

Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.

Tanaka Y, Sasaki M, Shiina H, Tokizane T, Deguchi M, Hirata H, Hinoda Y, Okayama N, Suehiro Y, Urakami S, Kawakami T, Kaneuchi M, Pookot D, Igawa M, Okuyama A, Ishii N, Dahiya R.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):238-44.

18.

Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Int J Cancer. 2005 Aug 20;116(2):174-81.

19.

The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.

Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ, Dahiya R.

Clin Cancer Res. 2003 Jun;9(6):2121-32.

Supplemental Content

Loading ...
Support Center